AZ sets up Alzheimer’s research collaborative
pharmafile | July 13, 2012 | News story | Research and Development | Alzheimer's, AstraZeneca, neuroscience
AstraZeneca and Dr Steven Paul of Weill Cornell Medical College have unveiled a new research alliance that brings four leading academic research laboratories together with AstraZeneca to study a major risk factor for Alzheimer’s disease, the apolipoprotein E4 genotype (ApoE).
The new collaboration is to be called the A5 alliance, and includes Dr Paul of the Helen and Robert Appel Alzheimer’s Disease Research Institute at Weill Cornell, Dr David Holtzman of Washington University in St Louis, Dr Peter Davies of The Feinstein Institute for Medical Research and Dr Cheryl Wellington of the University of British Columbia.
ApoE is considered second only to age as a risk factor for the development of Alzheimer’s disease. However, drug discovery efforts involving ApoE have been hampered by challenging biology and a lack of in-vivo models.
The A5 alliance members represent a team of academic scientists with expertise in ApoE biology who will focus on identification, validation, and risk reduction of drug targets for treatment of Alzheimer’s disease.
Dr Steven Paul, principal academic collaborator for the A5 alliance and director of the Helen and Robert Appel Alzheimer’s Disease Research Institute and professor of neuroscience, psychiatry and pharmacology at Weill Cornell, said: “The formation of the A5 alliance represents a unique academic-industry partnership whereby these Alzheimer’s disease experts will link their labs together and work closely with a pharmaceutical company to unlock the science behind ApoE in order to discover new disease-modifying drug targets.
“We are convinced that ApoE represents a major piece of the Alzheimer’s disease puzzle and that each member of the A5 alliance brings a critical piece of that puzzle to the table.”
Dr Menelas Pangalos, executive vice president of Innovative Medicines, AstraZeneca, said: “In February, AstraZeneca initiated a new, flexible approach to neuroscience that would allow us to tap into the most exciting science and discoveries that exist in labs around the world.
“The A5 alliance, under the leadership of Dr Paul, is a prime example of the great minds we hope to bring together in the search for new medicines to help people who suffer from neurodegenerative diseases, psychiatric disorders and pain.”
The A5 alliance will be funded by AstraZeneca and the academic research and members of the firm’s Neuroscience Innovative Medicines unit will contribute programme management and scientific expertise.
The academic alliance members will contribute their disease area knowledge and expertise, as well as lead specific aspects of the research programme in their laboratories.
Related Content
Evotec shares progress in Bristol Myers Squibb neuroscience collaboration
Evotec has announced that it has reached important scientific progress within the neuroscience collaboration with …
FDA accepts Eisai’s Leqembi sBLA for early AD treatment
Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted …
AstraZeneca shares results from phase 3 TROPION-Lung01 trial
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s …
